| scholarly article | Q13442814 |
| P50 | author | Lotte Bjerre Knudsen | Q58586406 |
| P2093 | author name string | Kevin L Grove | |
| Niels Vrang | |||
| Kristy M Heppner | |||
| Anna Secher | |||
| Melissa Kirigiti | |||
| Charles Pyke | |||
| Sarah Juel Paulsen | |||
| Rikley Buckingham | |||
| P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
| Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 | ||
| The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness | Q28216072 | ||
| Hypothalamic CART is a new anorectic peptide regulated by leptin | Q28271095 | ||
| Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | Q28571689 | ||
| The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss | Q30596646 | ||
| Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging | Q30757529 | ||
| The putative neuropeptide TAFA5 is expressed in the hypothalamic paraventricular nucleus and is regulated by dehydration | Q33319912 | ||
| Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats | Q33567269 | ||
| Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults | Q33570118 | ||
| Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults | Q33737073 | ||
| Cardiovascular and hemodynamic effects of glucagon-like peptide-1. | Q33993725 | ||
| GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure | Q34336097 | ||
| Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward | Q34685472 | ||
| Preproglucagon neurons project widely to autonomic control areas in the mouse brain. | Q34981134 | ||
| Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. | Q35110843 | ||
| Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes | Q35677365 | ||
| Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake | Q35893496 | ||
| Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis | Q35960169 | ||
| Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake | Q36807579 | ||
| Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans | Q36877627 | ||
| Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. | Q36979291 | ||
| Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei | Q37106861 | ||
| Role of central glucagon-like peptide-1 in stress regulation | Q37185214 | ||
| Liraglutide: a new treatment for type 2 diabetes | Q37431559 | ||
| AVP neurons in the paraventricular nucleus of the hypothalamus regulate feeding | Q37636433 | ||
| Is the GLP-1 system a viable therapeutic target for weight reduction? | Q37845218 | ||
| GLP-1 and energy balance: an integrated model of short-term and long-term control | Q37885717 | ||
| Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus | Q37888159 | ||
| Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor | Q38016154 | ||
| An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists | Q38030616 | ||
| The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders | Q38045690 | ||
| Incretin-based therapies: focus on effects beyond glycemic control alone | Q38140803 | ||
| cAMP response element-binding protein in the amygdala is required for long- but not short-term conditioned taste aversion memory | Q38342475 | ||
| GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. | Q39030156 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study | Q39905736 | ||
| Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas | Q40920945 | ||
| Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. | Q42445138 | ||
| Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like Peptide 1 neurons | Q42684124 | ||
| GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. | Q43110155 | ||
| Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease | Q43207399 | ||
| Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
| The glucagon-like peptide-1 receptor--or not? | Q44489452 | ||
| CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. | Q44516249 | ||
| Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication | Q46278128 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats | Q46573231 | ||
| Blockade of central GLP-1 receptors prevents CART-induced hypophagia and brain c-Fos expression | Q46695989 | ||
| Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats | Q46880649 | ||
| Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder | Q46987369 | ||
| Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. | Q47273005 | ||
| Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. | Q47308234 | ||
| The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents | Q47935485 | ||
| The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. | Q47996706 | ||
| Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus | Q48103424 | ||
| GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting | Q48180523 | ||
| Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei | Q48204065 | ||
| Identification and localization of glucagon-like peptide-1 and its receptor in rat brain | Q48216174 | ||
| Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease | Q48270990 | ||
| Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial | Q48292140 | ||
| Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system | Q48306367 | ||
| Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats | Q48456704 | ||
| Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment | Q48479423 | ||
| Cortical substrates of taste aversion learning: involvement of dorsolateral amygdaloid nuclei and temporal neocortex in taste aversion learning | Q48503001 | ||
| Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats | Q48509864 | ||
| PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats | Q48540815 | ||
| Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. | Q48599985 | ||
| GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans | Q48632540 | ||
| Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro | Q48660047 | ||
| Psychological and quality of life changes in patients using GLP-1 analogues | Q48665369 | ||
| Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem | Q48794136 | ||
| Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus | Q48883013 | ||
| Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats | Q48905629 | ||
| Expression of the glucagon-like peptide-1 receptor gene in rat brain. | Q49087428 | ||
| The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. | Q51011184 | ||
| Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I | Q58012594 | ||
| GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats | Q60302563 | ||
| Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study | Q68415323 | ||
| Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites | Q70905833 | ||
| Entry of exendin-4 into brain is rapid but may be limited at high doses | Q73107463 | ||
| Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats | Q73195050 | ||
| Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial | Q79294714 | ||
| The brainstem preproglucagon system in a non-human primate (Macaca mulatta) | Q84195464 | ||
| GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice | Q85538281 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rhesus macaque | Q156606 |
| primate brain | Q51286653 | ||
| P304 | page(s) | 255-267 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain | |
| P478 | volume | 156 |
| Q54961751 | A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q99404602 | Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function |
| Q90657723 | Association Between GLP-1 Receptor Gene Polymorphisms with Reward Learning, Anhedonia, and Depression Diagnosis |
| Q64091576 | Crosstalk between gut microbiota and antidiabetic drug action |
| Q48300731 | DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain |
| Q37558852 | Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress. |
| Q28600938 | Distribution and Abundance of Glucocorticoid and Mineralocorticoid Receptors throughout the Brain of the Great Tit (Parus major) |
| Q34499374 | Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain |
| Q58091552 | Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys |
| Q47144778 | Endocrine Disruptors Leading to Obesity and Related Diseases. |
| Q59796227 | Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment |
| Q48500262 | Equine glucagon-like peptide-1 receptor physiology. |
| Q90051591 | GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats |
| Q38794234 | GLP-1 and weight loss: unraveling the diverse neural circuitry |
| Q35200252 | GLP-1 based therapeutics: simultaneously combating T2DM and obesity. |
| Q34511743 | GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-cont |
| Q30354371 | GLP-1R Signaling Directly Activates Arcuate Nucleus Kisspeptin Action in Brain Slices but Does not Rescue Luteinizing Hormone Inhibition in Ovariectomized Mice During Negative Energy Balance. |
| Q47153467 | Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39). |
| Q64092426 | Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs |
| Q38753804 | Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis |
| Q90366981 | Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q92513493 | Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury |
| Q36653883 | Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice |
| Q36078803 | Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease |
| Q26749191 | Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus |
| Q38589032 | Mechanisms for the cardiovascular effects of glucagon-like peptide-1. |
| Q45159552 | Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats |
| Q90236862 | Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases |
| Q47785459 | No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia |
| Q41986529 | Obesity as a risk factor for Alzheimer's disease: weighing the evidence |
| Q36339320 | PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. |
| Q93340208 | Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q90661474 | Semaglutide lowers body weight in rodents via distributed neural pathways |
| Q26738730 | Targeting the gastrointestinal tract to treat type 2 diabetes |
| Q64118590 | The Discovery and Development of Liraglutide and Semaglutide |
| Q42125458 | The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. |
| Q26799942 | The L-Cell in Nutritional Sensing and the Regulation of Appetite |
| Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
Search more.